|
Home : Medical Devices : Gadolinium & Nephrogenic Systemic Fibrosis (NSF) : Newsfeeds : Laquinimod Beneficial in Reducing Multiple Sclerosis Relapse Rate in Clinical Trials Laquinimod Beneficial in Reducing Multiple Sclerosis Relapse Rate in Clinical Trials
The primary endpoint was annualized relapse rate and secondary endpoints included the cumulative number of gadolinium-enhancing and new or newly enlarging T2 lesions. The patients were also measured on the Expanded Disability Status Scale (EDSS ...
Find a Gadolinium & Nephrogenic System Fibrosis (NSF) Lawyer Now
This form is secure and encrypted. More information about secure forms and your privacy here.
|




